Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase III trial comparing obinutuzumab to Rituxan in CLL meets primary endpoint

July 24, 2013

Genmab submits IND to conduct phase I study of HuMax-TF-ADC

July 24, 2013

Kyowa Hakko Kirin files application in Japan to expand indication for mogamulizumab

July 19, 2013

NCIC Clinical Trials Group to conduct phase II DPX-Survivac study

July 16, 2013

Erivedge receives conditional E.U. approval

July 16, 2013

Idiotype-based vaccine induces immune response against neuroblastoma

July 11, 2013

Radioimmunotherapy proves safe in metastatic pancreatic cancer patients

July 11, 2013

Bellicum Pharmaceuticals begins trial of novel controlled dendritic cell immunotherapy

July 10, 2013

Results from first-in-human study of VXM-01 reported

July 10, 2013

Margetuximab well tolerated and active in phase I solid tumors trial

July 9, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...